MK-8591

Drug Merck Sharp & Dohme Corporation
Total Payments
$7.9M
Transactions
1,601
Doctors
23
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2020 $4.7M 544 6
2019 $1.1M 535 14
2018 $1.2M 434 1
2017 $843,502 88 5

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $7.9M 1,459 99.6%
Consulting Fee $13,275 15 0.2%
Travel and Lodging $11,663 52 0.1%
Food and Beverage $3,702 75 0.0%

Payments by Type

Research
$7.9M
1,459 transactions
General
$28,639
142 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low-Risk for HIV-1 Infection Merck Sharp & Dohme Corporation $3.5M 0
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral-Activity, and Pharmacokinetics of MK 8591 Given in Combination with Doravirine DOR and Lamivudine 3TC in HIV-1-Infected Treatment-Na ve Adults Merck Sharp & Dohme Corporation $2.2M 0
A Multiple-Dose Study to Assess the Safety and Pharmacokinetics of Daily MK 8591 Administration in Healthy Adult Subjects Merck Sharp & Dohme Corporation $642,916 0
A Single-dose Double-blind Study to Assess the Safety and Pharmacokinetics of a Radiopaque Matrix MK-8591 Implant in Healthy Adult Subjects Merck Sharp & Dohme Corporation $307,879 0
A study to evaluate the potential interaction of MK-8591 with MK-1439 in healthy adult subjects Merck Sharp & Dohme Corporation $280,017 0
A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Islatravir MK-8591 on the QTc Interval in Healthy Adult Participants Merck Sharp & Dohme Corporation $208,542 0
Study to evaluate post-exposure prophylaxis of MK-8591 in a rhesus macaque model using SIV. Merck Sharp & Dohme Corporation $200,000 0
A Study to Investigate the Absorption, Metabolism, and Excretion of MK-8591 Islatravir in Healthy Adult Subjects Merck Sharp & Dohme Corporation $142,773 0
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir MK-8591 in Subjects with Severe Renal Impairment Merck Sharp & Dohme Corporation $117,237 0
A double-blind placebo-controlled single rising dose trial of intramuscular IM and subcutaneous SC administration of MK-8591 in healthy participants Merck Sharp & Dohme Corporation $85,800 0
A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir ISL and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF Once-Daily Merck Sharp & Dohme Corporation $78,078 0
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir MK-8591 in Participants with Moderate Hepatic Impairment Merck Sharp & Dohme Corporation $55,935 0
A Study to Assess the Effects of Multiple, Once Weekly Oral Doses of MK-8591 on theSingle-Dose Pharmacokinetics of an Oral Contraceptive Levonorgesterel and EthinylEstradiol in Healthy Adult Postmenopausal or Oopherectomized Female Subjects Merck Sharp & Dohme Corporation $50,297 0
A Single-dose Study to Assess the Safety and Pharmacokinetics of an MK-8591 Implant in Healthy Adult Subjects Merck Sharp & Dohme Corporation $15,553 0
A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection Merck Sharp & Dohme Corporation $500.00 0
A Clinical Trial to Study the Effect of a Single Dose of Islatravir MK-8591 on the Pharmacokinetics of Methadone Merck Sharp & Dohme Corporation $303.80 0

Top Doctors Receiving Payments for MK-8591

Doctor Specialty Location Total Records
Unknown — Pittsburgh, PA $7.9M 1,461
, MD Hematology & Oncology San Francisco, CA $5,475 5
, M.D Internal Medicine San Francisco, CA $2,794 10
, MD Internal Medicine Los Angeles, CA $2,250 4
Princy Kumar Infectious Disease Washington, DC $1,955 11
, M.D Infectious Disease Sacramento, CA $1,574 9
, MD Internal Medicine Providence, RI $1,549 11
, MD Infectious Disease Chapel Hill, NC $1,401 5
, MD Infectious Disease Cleveland, OH $1,225 1
, M.D Internal Medicine New York, NY $1,225 1
, MD Internal Medicine Lincoln, NE $1,184 11
, MD Infectious Disease Los Angeles, CA $1,131 7
Heidi Crane Infectious Disease Seattle, WA $1,125 1
, D.O Geriatric Medicine Phoenix, AZ $992.26 10
, MD Infectious Disease Dallas, TX $887.73 7
, MD Internal Medicine Bellaire, TX $764.32 7
, MD Specialist Pittsburgh, PA $670.96 8
, M.D Gastroenterology Hollywood, FL $576.52 6
, MD Infectious Disease Boston, MA $417.41 5
, M.D Infectious Disease Baltimore, MD $417.41 5
, M.D Clinical Pharmacology Baltimore, MD $409.58 5
, MD Internal Medicine Boston, MA $203.28 4
, MD Infectious Disease Washington, DC $158.23 4
, M.D Infectious Disease Atlanta, GA $131.08 3

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $7.9M
  • Total Doctors 23
  • Transactions 1,601

About MK-8591

MK-8591 is a drug associated with $7.9M in payments to 23 healthcare providers, recorded across 1,601 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.

Payment data is available from 2017 to 2020. In 2020, $4.7M was paid across 544 transactions to 6 doctors.

The most common payment nature for MK-8591 is "Unspecified" ($7.9M, 99.6% of total).

MK-8591 is associated with 16 research studies, including "A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low-Risk for HIV-1 Infection" ($3.5M).